CHICAGO -- Intracerebroventricular (ICV) delivery of bivalent CAR T-cells targeting EGFR and IL13Rα2 was feasible and appeared safe in patients with recurrent glioblastoma (GBM) in a phase I study ...
- Nature Medicine publication describes how GENESIS trial included patients representative of current multiple myeloma population undergoing autologous HSCT, including older patients and those who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback